In the past decade, an explosion of new treatments, including those with novel mode of actions, have revolutionised the psoriasis armamentarium. How many patients can expect to benefit from these new treatments? What are the ongoing unmet needs among patients with psoriasis? How have the new therapies influenced the current treatment guidelines and what can we expect in the near future? Professor Paolo Gisondi and Professor Rolland Gyulai (click to see biographies and disclosures) address these topics and more in the following video series.
How many people experience psoriasis and how does that differ geographically? In this video, Professors Gisondi and Gyulai highlight the general prevalence rates for psoriasis, address how this is affected by geography, and describe the relative psoriasis severity levels within the patient population.
Psoriasis is a debilitating chronic condition, but what are the most pressing unmet needs? Watch our experts discuss undertreatment, treatment longevity and how the most difficult to treat patients may not be those with severe disease.
Psoriasis can prevent a range of daily problems to patients, impacting their day-to-day quality of life. However, its not just the physical burden that is an issue. Our experts address quality of life in patients with psoriasis and provide insights into the psychological burden of the disease.
Psoriasis is not just a skin disease. While psoriatic arthritis may be the most common comorbidity, our experts discuss the impact of other comorbidities such as cardiovascular and metabolic conditions.
In recent years, the efficacy of psoriasis treatments has substantially improved and seen treatment goals increase from PASI 50 to PASI 75. However, should we be aiming higher than PASI 75 now that PASI 100 is achievable for many patients? Our experts offer their thoughts on what the most appropriate treatment goal is, how this may differ between counties and the need to listen to the patient.
When choosing a treatment for your patients with psoriasis what do you consider? Cost, effectiveness? Professor Paolo Gisondi and Professor Rolland Gyulai discuss the importance of considering treatment longevity due to the chronic nature of psoriatic disease.
With several new treatments being approved in recent years, how have the guidelines changed and what do we expect to see in the future? Watch our experts discuss the addition of secukinumab and apremilast to the guidelines and the approval of new anti-IL-17 and anti-IL-23 therapies.